KT5823 A selective inhibitor of cGKI and spontaneous apoptosis

KT5823 (CAS 126643-37-6)

KT5823 | CAS 126643-37-6 is rated 5.0 out of 5 by 1.
  • y_2018, m_4, d_19, h_3
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_3534, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 145ms
  • REVIEWS, PRODUCT
| See product citations (16)
Synonym: KT-5823
Application: A selective inhibitor of cGKI and spontaneous apoptosis
CAS Number: 126643-37-6
Purity: ≥97%
Molecular Weight: 495.5
Molecular Formula: C29H25N3O5
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ordering Information

PRODUCT NAME CATALOG # UNIT PRICE QTY FAVORITES
KT5823 sc-3534 100 µg $143.00

KT5823 is a derivative of K-252a (sc-200517) and a selective inhibitor of cGMP-dependent protein kinases (cGKI, Ki=2.4nM) in vitro, but does not inhibit cGMP-dependent protein kinase phosphorylation of VASP in either intact platelets or rat mesangial cells. KT5823 has also been shown to dose-dependently inhibit spontaneous apoptosis of neutrophils, thus suggesting cGK as a mediator of neutrophil spontaneous apoptosis.


References

1. Hidaka, H., et al. 1984. Biochemistry. 23: 5036-5041. PMID: 6238627
2. Kase, H., et al. 1987. Biochem. Biophys. Res. Commun. 142: 436-440. PMID: 3028414
3. Burkhardt, M., et al. 2000. J. Biol. Chem. 275: 33536-33541. PMID: 10922374
4. Brunetti, M., et al. 2002. Biochem. Biophys. Res. Commun. 297: 498-501. PMID: 12270121

Physical State :
Solid
Solubility :
Soluble in water (partly miscible), DMSO (20 mg/ml), DMF (20 mg/ml), and ethyl acetate (5 mg/ml).
Storage :
Store at -20° C
Boiling Point :
~629.2° C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
Refractive Index :
n20D 1.76 (Predicted)
IC50 :
SNP-stimulated PKG activity: IC50 = 60 nM (dispersed smooth muscle cells)
Ki Data :
PKG: Ki= 0.23 µM; PKC: Ki= 4 µM; PKA: Ki> 10 µM; MLCK: Ki>10 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
3843
MDL Number :
MFCD09878278
SMILES :
CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CN(C6=O)C)(C(=O)OC)OC

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

You May Also Like

KT5823Product Citations

See how others have used KT5823. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 16 total

PMID: # 28245258
Asensio-López, MC. et al. 2017. Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE. 12: e0172803.

PMID: # 27148059
Pinto, I. et al. 2016. The Role of cGMP on Adenosine A 1 Receptor-mediated Inhibition of Synaptic Transmission at the Hippocampus. Frontiers in pharmacology. 7: 103.

PMID: # 25963768
Nethi, SK. et al. 2015. Investigation of molecular mechanisms and regulatory pathways of pro-angiogenic nanorods. Nanoscale. 7: 9760-70.

PMID: # 25249574
Roberts, LD. et al. 2015. Inorganic nitrate promotes the browning of white adipose tissue through the nitrate-nitrite-nitric oxide pathway. Diabetes. 64: 471-84.

PMID: # 23174781
Zhou, L. et al. 2013. Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway. Hepatology (Baltimore, Md.). 57: 1384-93.

PMID: # 18406400
Wang, J. et al. 2008. Involvement of the nitric oxide-cyclic GMP-protein kinase G-K+ channel pathway in the antihyperalgesic effects of bovine lactoferrin in a model of neuropathic pain. Brain research. 1209: 1-7.

PMID: # 18218984
Kunieda, T. et al. 2008. Reduced nitric oxide causes age-associated impairment of circadian rhythmicity. Circ. Res.. 102: 607-614.

PMID: # 17568572
Selemidis, S. et al. 2007. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc. Res.. 75: 349-358.

PMID: # 17513385
Yeh, W.L. et al. 2007. Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1alpha accumulation and VEGF expression Mol Pharmacol. . 72: 440-449.

PMID: # 16242122
Chae, H.J. et al. 2006. Carbon monoxide and nitric oxide protect against tumor necrosis factor-alpha-induced apoptosis in osteoblasts: HO-1 is necessary to mediate the protection Clin. Chim. Acta.. 365: 270-278.

Citations 1 to 10 of 16 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 64ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Zhou Zhou, et. al. (PubMed ID 23174781) used KT5823, purchased from SCBT, along with other inhibitors to clarify resistan's signal transduction pathway. HepG2 cells were used with a dosage of 50nM. -SCBT Publication Review
Date published: 2015-05-07
  • y_2018, m_4, d_19, h_3
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.8
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_3534, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 135ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2018 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.